Enterocolitis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Enterocolitis – Pipeline Review, H2 2016’, provides an overview of the Enterocolitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Enterocolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Enterocolitis

The report reviews pipeline therapeutics for Enterocolitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Enterocolitis therapeutics and enlists all their major and minor projects

The report assesses Enterocolitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Enterocolitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Enterocolitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Enterocolitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Angothera GmbH

AvidBiotics Corp.

Infant Bacterial Therapeutics AB

Sigma-Tau Pharmaceuticals, Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Enterocolitis Overview 6

Therapeutics Development 7

Pipeline Products for Enterocolitis - Overview 7

Pipeline Products for Enterocolitis - Comparative Analysis 8

Enterocolitis - Therapeutics under Development by Companies 9

Enterocolitis - Therapeutics under Investigation by Universities/Institutes 10

Enterocolitis - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Enterocolitis - Products under Development by Companies 13

Enterocolitis - Products under Investigation by Universities/Institutes 14

Enterocolitis - Companies Involved in Therapeutics Development 15

Angothera GmbH 15

AvidBiotics Corp. 16

Infant Bacterial Therapeutics AB 17

Sigma-Tau Pharmaceuticals, Inc 18

Enterocolitis - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 25

Drug Profiles 27

Antibodies for Enterocolitis - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

AvR2-V10 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

C-34 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

IBP-9414 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

melatonin - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

NRG-4 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecules for Necrotizing Enterocolitis - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

STP-206 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Enterocolitis - Dormant Projects 38

Enterocolitis - Product Development Milestones 39

Featured News & Press Releases 39

Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial 39

Mar 31, 2016: IBT receives Rare Pediatric Disease Designation from FDA for drug candidate 39

Jan 08, 2016: BioGaia’s subsidiary IBT has US IND open and Swedish CTA approved for clinical study 39

Jun 24, 2015: BioGaia Subsidiary IBT Takes Rapid Steps in Development of a Drug for Premature Infants 40

Jun 12, 2015: BioGaia evaluates the possibility of a separate listing of Infant Bacterial Therapeutics 40

Mar 26, 2015: Infant Bacterial Therapeutics receives additional funding from mother company BioGaia 40

Feb 23, 2015: BioGaia subsidiary Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe 41

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Tables

List of Tables

Number of Products under Development for Enterocolitis, H2 2016 7

Number of Products under Development for Enterocolitis – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Enterocolitis – Pipeline by Angothera GmbH, H2 2016 15

Enterocolitis – Pipeline by AvidBiotics Corp., H2 2016 16

Enterocolitis – Pipeline by Infant Bacterial Therapeutics AB, H2 2016 17

Enterocolitis – Pipeline by Sigma-Tau Pharmaceuticals, Inc, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Enterocolitis – Dormant Projects, H2 2016 38

List of Figures

List of Figures

Number of Products under Development for Enterocolitis, H2 2016 7

Number of Products under Development for Enterocolitis – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Types, H2 2016 25

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports